Becton Dickinson returns to New Jersey after California visit the week of key earnings and FDA issues

Becton Dickinson flew from John Wayne Airport in Orange County to Morristown Municipal Airport on June 20, a 4-hour-23-minute hop aboard its Falcon 7X, N294X. The medical-device giant had departed New Jersey for California just a day earlier, returning to its Franklin Lakes headquarters as the week drew to a close.

The trip comes on the heels of a busy period for Becton Dickinson. On May 7, the company reported fiscal second-quarter 2026 earnings that beat expectations, with revenue of $4.7 billion and a raised full-year adjusted EPS outlook, per [investors.bd.com](https://investors.bd.com/news-events/press-releases/detail/958/bd-reports-second-quarter-fiscal-2026-financial-results). CEO Tom Polen highlighted “strong performance” across more than 90% of the business. The company also recently completed a spin-off of its Biosciences and Diagnostic Solutions unit (completed February 9, per [SEC filings](https://www.sec.gov/Archives/edgar/data/10795/000162828026031638/bdx-20260507.htm)), and is managing fallout from an FDA Warning Letter at its El Paso plant and a voluntary ship hold on ChloraPrep and PurPrep products in May, as noted in a May 29 current report on [investors.bd.com](https://investors.bd.com/sec-filings/all-sec-filings/content/0001628280-26-039005/bdx-20260529.htm).

The Orange County detour—a rare destination for Becton Dickinson, which usually shuttles between New Jersey and Washington, Chicago, London, Frankfurt, or San Francisco—suggests a specific business meeting or site visit. California is home to key hospital systems and med-tech partners, and the state remains a major market for the company's AI-powered medication management and catheter systems. The quick round trip underscores a return to headquarters to steady the ship amid regulatory headwinds and post-spin integration.